March 22nd 2023
Retifanlimab has received accelerated approved for patients with metastatic or recurrent, locally advanced merkel cell carcinoma.
December 23rd 2022
December 13th 2022
Real-World Study Demonstrates Benefits with Adjuvant Nivolumab in Resected Stage IIIA MelanomaNovember 14th 2022
A significant portion of patients with resected stage IIIA melanoma were alive and recurrence free at a median follow-up of over 20 months following treatment with adjuvant nivolumab.
Investigators Identify Immunotherapy Followed by BRAK/MEK Inhibition as Optimal Sequence Strategy in BRAF+ MelanomaOctober 11th 2022
Optimal treatment sequencing for patients with BRAF-mutated melanoma involves frontline immunotherapy following by BRAF/MEK inhibition, according to investigators.
Rise of Oral Cancer Drugs Signal Deeper Financial Toxicity Issues for PatientsSeptember 28th 2022
Mary Anderson, BSN, RN, OCN; and Christina Bach, MBE, MSW, LCSW, OSW-C, FAOSW, discuss approaches to help patients navigate financial toxicity and insurance coverage in the age of oral anticancer drugs.
Pembrolizumab Potentially Most Effective Before Surgery in High-Risk MelanomaSeptember 18th 2022
The rate of event-free survival associated with pembrolizumab was significantly higher among patients with high-risk melanoma about to undergo surgery than among those who received immunotherapy following surgery.
5-Year Follow-Up Shows Neoadjuvant T-VEC Benefit in Patients with Resectable MelanomaSeptember 13th 2022
The relapse-free survival rate was 22.3% among patients with resectable stage IIIB to IV M1a melanoma who received neoadjuvant talimogene laherparepvec versus 15.2% among those who received surgery alone.
7.5-Year Follow-Up Affirms Nivolumab’s Superiority Over Ipilimumab in Advanced MelanomaJuly 13th 2022
Nivolumab, whether in combination with ipilimumab or as a monotherapy, was associated with improved overall survival, progression-free survival, and melanoma-specific survival, compared with ipilimumab in advanced melanoma.
Are Oncology Nurses Underutilized in Positively Affecting the Opioid Epidemic?July 7th 2022
Gretchen McNally PhD, ANP-BC, AOCNP, discusses the potential impact advanced practice providers and nurses could have in the opioid pandemic if the correct educational opportunities were available.